Lisa Chan Lei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lisa Chan Lei has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Josephine Mun-Yee Ko
Department of Clinical Oncology, Centre of Cancer Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong (Special Administrative Region), Hong Kong, People's Republic of China.
25 shared publications - Maria Li Lung
Department of Clinical Oncology, Centre of Cancer Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong (Special Administrative Region), Hong Kong, People's Republic of China
25 shared publications Candy King-Chi Chan
22 shared publications- Wei Dai
University of Hong Kong
22 shared publications - Dittman Lai-Shun Chung
Department of Clinical Oncology, University of Hong Kong, Pokfulam, Hong Kong (SAR), P. R. China
21 shared publications - Merrin Man-Long Leong
Department of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
21 shared publications
Latest Publications
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Clinical Outcome–Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma
Figure S6: Methylation of selected genes between signature 3-positive and -negative groups.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Clinical Outcome–Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma
Figure S6: Methylation of selected genes between signature 3-positive and -negative groups.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Clinical Outcome–Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma
Figure S5: Methylation of selected genes between NPC and adjacent non-tumor tissues.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Clinical Outcome–Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma
Figure S5: Methylation of selected genes between NPC and adjacent non-tumor tissues.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Clinical Outcome–Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma
Figure S7: Distinct host and EBV methylation in NPC cases with BRCAness signature. (A) Differential methylation between signature-positive and -negative cases measured by Illumina HumanMethylation450 array. (B) EBV methylation between signature-positive and -negative cases. Differential methylation was observed at two regions. (C) Differential methylation at EBV genome for two selected regions. (D) Ratios of LMP-1 and LMP-2A expression between signature-positive and -negative groups.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Clinical Outcome–Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma
Figure S7: Distinct host and EBV methylation in NPC cases with BRCAness signature. (A) Differential methylation between signature-positive and -negative cases measured by Illumina HumanMethylation450 array. (B) EBV methylation between signature-positive and -negative cases. Differential methylation was observed at two regions. (C) Differential methylation at EBV genome for two selected regions. (D) Ratios of LMP-1 and LMP-2A expression between signature-positive and -negative groups.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Clinical Outcome–Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma
Figure S4: Kaplan-Meier plot of progression-free survival (PFS) in the HK-1 cohort. The patients were categorized into two groups. One group has both detectable signature 3 and MMR signature and the remaining cases are in the other group. The hazard ratio was estimated by the univariate Cox analysis.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Clinical Outcome–Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma
Figure S4: Kaplan-Meier plot of progression-free survival (PFS) in the HK-1 cohort. The patients were categorized into two groups. One group has both detectable signature 3 and MMR signature and the remaining cases are in the other group. The hazard ratio was estimated by the univariate Cox analysis.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Clinical Outcome–Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma
Figure S3: COSMIC signature contributions. Annotation of the signature is obtained from the Cosmic database (https://cancer.sanger.ac.uk/cosmic/signatures_v2).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Clinical Outcome–Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma
Figure S3: COSMIC signature contributions. Annotation of the signature is obtained from the Cosmic database (https://cancer.sanger.ac.uk/cosmic/signatures_v2).
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Clinical Outcome–Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma
Figure S2: The factorization rank plot estimated by the R package NMF.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Clinical Outcome–Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma
Figure S2: The factorization rank plot estimated by the R package NMF.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S8 (clean version) from Clinical Outcome–Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma
Table S1: Clinical parameters for the HK-3 cohort for targeted sequencing (N=402);Table S2: Sample size estimation and power calculation for study cohorts;Table S3: Mutational signatures and clinical parameters in primary NPC (N=178);Table S4: All the pathogenic germline and somatic alterations at BRCA2 (NM_000059) detected in NPC (N=216);Table S5: Germline and somatic alterations at the selected DNA damage and repair genes in 216 NPC cases for the genes with differential expression and SCNAs in NPC;Table S6: Germline rare variants detected at BRCA2 (NM_000059) in the HK-3 cohort (N=402);Table S7: Association of BRCA2 germline rare variants with clinical parameters in the HK-3 cohort (N=402);Table S8: Differentially methylated CpG sites between signature 3-positive and -negative cases
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S8 (clean version) from Clinical Outcome–Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma
Table S1: Clinical parameters for the HK-3 cohort for targeted sequencing (N=402);Table S2: Sample size estimation and power calculation for study cohorts;Table S3: Mutational signatures and clinical parameters in primary NPC (N=178);Table S4: All the pathogenic germline and somatic alterations at BRCA2 (NM_000059) detected in NPC (N=216);Table S5: Germline and somatic alterations at the selected DNA damage and repair genes in 216 NPC cases for the genes with differential expression and SCNAs in NPC;Table S6: Germline rare variants detected at BRCA2 (NM_000059) in the HK-3 cohort (N=402);Table S7: Association of BRCA2 germline rare variants with clinical parameters in the HK-3 cohort (N=402);Table S8: Differentially methylated CpG sites between signature 3-positive and -negative cases